306 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
INCY Incyte Corporation $67.04 $14.25B N/A
Article Searches
Merck's Keytruda Gets Priority Review for Rare Skin Cancer http://www.zacks.com/stock/news/321571/mercks-keytruda-gets-priority-review-for-rare-skin-cancer?cid=CS-ZC-FT-321571 Sep 05, 2018 - Merck's (MRK) sBLA for Keytruda to expand its label for a rare form of skin cancer gets priority review from FDA.
Agenus' (AGEN) Q2 Loss Narrower Than Expected, Revenues Beat http://www.zacks.com/stock/news/317485/agenus-agen-q2-loss-narrower-than-expected-revenues-beat?cid=CS-ZC-FT-317485 Aug 10, 2018 - Agenus (AGEN) posts narrower-than-expected loss in the second quarter of 2018 and expects to file three investigational new drugs by the end of 2018.
The 3 Worst Healthcare Stocks of 2018 (So Far) https://www.fool.com/investing/2018/07/19/the-3-worst-healthcare-stocks-of-2018-so-far.aspx?source=iedfolrf0000001 Jul 19, 2018 - Find out how three companies have lost their shareholders a combined $31 billion so far this year.
CTI BioPharma Tanks Post Type B Talks on Pacritinib With FDA http://www.zacks.com/stock/news/312300/cti-biopharma-tanks-post-type-b-talks-on-pacritinib-with-fda?cid=CS-ZC-FT-312300 Jul 19, 2018 - CTI BioPharma (CTIC) conducts Type B meeting with the FDA to discuss a regulatory pathway for its lead pipeline candidate Pacritinib, currently under study for the treatment of myelofibrosis.
Can Eli Lilly (LLY) Keep the Earnings Streak Alive in Q2? http://www.zacks.com/stock/news/312213/can-eli-lilly-lly-keep-the-earnings-streak-alive-in-q2?cid=CS-ZC-FT-312213 Jul 19, 2018 - Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.
Merck's Keytruda Gets Priority Review in Difficult Lung Cancer http://www.zacks.com/stock/news/310183/mercks-keytruda-gets-priority-review-in-difficult-lung-cancer?cid=CS-ZC-FT-310183 Jul 03, 2018 - Merck's (MRK) sBLA looking to expand the label of Keytruda for first-line treatment of metastatic squamous NSCLC gets FDA's priority review. The decision is expected on Oct 30.
Better Know Biotech: 2 Stocks You've Got to Know About https://www.fool.com/investing/2018/06/01/better-know-biotech-2-stocks-you-better-know-about.aspx?source=iedfolrf0000001 Jun 01, 2018 - These two small-cap biotech stocks could be about to make it big.
Incyte (INCY) Up 10.2% Since Earnings Report: Can It Continue? http://www.zacks.com/stock/news/305890/incyte-incy-up-102-since-earnings-report-can-it-continue?cid=CS-ZC-FT-305890 May 31, 2018 - Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
3 Biotechs With Huge FDA Decisions in June https://www.fool.com/investing/2018/05/31/3-biotechs-with-huge-fda-decisions-in-june.aspx?source=iedfolrf0000001 May 31, 2018 - The clock is ticking for these biotechs hoping to score key regulatory victories.
5 Things AbbVie Investors Need to Know https://www.fool.com/investing/2018/05/18/5-things-abbvie-investors-need-to-know.aspx?source=iedfolrf0000001 May 18, 2018 - AbbVie's top executives answer tough questions about the company's products and pipeline.

Pages: 1...89101112131415161718...31

<<<Page 13>